Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereotactic body radiotherapy in early-stage hepatocellular carcinoma: a systematic review and meta-analysis.

ESMO gastrointestinal oncology·2026
Same author

Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy.

European journal of nuclear medicine and molecular imaging·2026
Same author

Near complete response recurrent glioblastoma after treatment with [<sup>131</sup>I]-Iodofalan.

European journal of nuclear medicine and molecular imaging·2026
Same author

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET).

ESMO open·2025
Same author

Efficacy of Intra-arterial [<sup>177</sup>Lu]Lu-DOTATATE monotherapy for treatment-refractory meningioma.

Journal of neuro-oncology·2025
Same author

Controversies in NEN: An ENETS position statement on the management of locally advanced neuroendocrine neoplasia of the small intestine and pancreas without distant metastases.

Journal of neuroendocrinology·2025

Related Experiment Video

Updated: Nov 24, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

853

Current Status and Future Direction of Hepatic Radioembolisation.

A A Alsultan1, A J A T Braat1, M L J Smits1

  • 1Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|December 28, 2020
PubMed
Summary

Radioembolisation, a liver cancer treatment, involves multiple stages like simulation and imaging. Recent advancements have improved these steps, with ongoing developments promising further progress in this locoregional therapy.

Keywords:
Hepatocellular carcinomaPETmetastatic colorectal cancerpersonalised dosimetryradioembolisation

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.9K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.6K

Related Experiment Videos

Last Updated: Nov 24, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

853
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.9K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.6K

Area of Science:

  • Interventional Radiology
  • Nuclear Medicine
  • Oncology

Background:

  • Radioembolisation is a key locoregional treatment for liver malignancies.
  • The procedure involves distinct stages: simulation, imaging, activity selection, treatment, and follow-up.
  • Significant advancements have occurred in radioembolisation techniques over the last decade.

Purpose of the Study:

  • To provide a comprehensive overview of current radioembolisation practices.
  • To identify and discuss the limitations of existing radioembolisation methods.
  • To explore emerging and promising developments in the field.

Main Methods:

  • Review of advancements in pre-treatment angiographic simulation.
  • Analysis of progress in nuclear medicine imaging for radioembolisation.
  • Evaluation of current treatment activity calculation and delivery methods.
  • Assessment of post-treatment imaging techniques and their evolution.

Main Results:

  • Multiple stages of radioembolisation have seen substantial technological and methodological improvements.
  • Current approaches have limitations that necessitate further research and development.
  • Promising new developments are emerging across all phases of the procedure.

Conclusions:

  • Radioembolisation is a rapidly evolving treatment modality for hepatic malignancies.
  • Continued innovation is crucial to overcome current limitations and enhance treatment efficacy.
  • Future directions hold significant potential for improving patient outcomes in liver cancer treatment.